L-type voltage-gated calcium channel (Cav1.x) (Cav1.x)

The Cav1.x family, commonly referred to as L-type voltage-gated calcium channels (LTCCs), comprises four distinct subtypes (Cav1.1, Cav1.2, Cav1.3, and Cav1.4) that are essential for electromechanical and electrosecretory coupling (StatPearls, 2023). These channels are characterized by their high-voltage activation and slow, "long-lasting" (L-type) inactivation kinetics, allowing for significant calcium influx during prolonged depolarization (UniProt, 2024). Cav1.1 is primarily expressed in skeletal muscle, while Cav1.2 and Cav1.3 are widely distributed in the heart, vascular smooth muscle, and the central nervous system, where they regulate contraction and gene expression (PubMed, PMID: 30236530). Cav1.4 is specialized for tonic neurotransmitter release in the retina (NCBI, 2023). Mutations or dysregulation of these channels are implicated in a variety of "channelopathies," including Timothy syndrome, Brugada syndrome, and hypertension (PubMed, PMID: 28137938). Clinically, Cav1 channels are the primary targets for calcium channel blockers like amlodipine and verapamil, which are cornerstone treatments for cardiovascular diseases (PubChem, 2024). Recent research also highlights their involvement in neurodegenerative processes, suggesting potential for new therapeutic applications in Parkinson's and Alzheimer's diseases (PubMed, PMID: 31554984).

Other names

L-type calcium channelLTCCDihydropyridine-sensitive calcium channelCav1 familyVoltage-dependent L-type calcium channel

Inhibition of calcium ion influx through the pore-forming alpha-1 subunit of the L-type calcium channel, resulting in smooth muscle relaxation and decreased myocardial contractility.